Citadel Advisors LLC Buys Shares of 40,968 Femasys Inc. (NASDAQ:FEMY)

Citadel Advisors LLC purchased a new position in shares of Femasys Inc. (NASDAQ:FEMY) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 40,968 shares of the company’s stock, valued at approximately $45,000.

Several other large investors also recently made changes to their positions in FEMY. Jane Street Group LLC acquired a new stake in Femasys in the 4th quarter worth approximately $30,000. Northern Trust Corp raised its position in shares of Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after purchasing an additional 37,675 shares during the period. Geode Capital Management LLC lifted its stake in shares of Femasys by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock worth $238,000 after buying an additional 9,681 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Femasys during the 4th quarter worth $25,000. Institutional investors own 65.27% of the company’s stock.

Femasys Stock Up 6.3%

FEMY opened at $0.85 on Thursday. The business has a 50 day moving average of $1.07 and a 200-day moving average of $1.20. The stock has a market capitalization of $21.72 million, a price-to-earnings ratio of -1.05 and a beta of -2.62. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. Femasys Inc. has a 1-year low of $0.69 and a 1-year high of $1.80.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.14 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. As a group, sell-side analysts anticipate that Femasys Inc. will post -0.86 earnings per share for the current year.

Wall Street Analyst Weigh In

FEMY has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Femasys in a report on Wednesday. Jones Trading dropped their price objective on Femasys from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th.

Femasys Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.